These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 1102193)

  • 1. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 3. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 5. [Blood platelet qualitative defects].
    Dioguardi N
    Minerva Med; 1974 Nov; 65(84):4351-61. PubMed ID: 4215988
    [No Abstract]   [Full Text] [Related]  

  • 6. [Phospholipids and platelet procoagulant activity in myeloproliferative syndromes].
    Martínez E; César J; Navarro JL; Mercado A; Pardo A; García Avello A; García Frade J
    Sangre (Barc); 1985; 30(1):22-7. PubMed ID: 4039850
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical conference: Histaaminemia in myeloproliferative syndromes].
    Cadiou M; Ruff F; Meunier F; Attalah N; Bernadou A; Zittoun R; Parrot JL; Bousser J
    Nouv Rev Fr Hematol; 1975; 15(2):261-9. PubMed ID: 126436
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 11. [The platelet defect in myeloproliferative disorder (author's transl)].
    Delobel J
    Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
    Berild D; Hasselbalch H; Knudsen JB
    Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo platelet release in myeloproliferative disorders.
    Ireland H; Lane DA; Wolff S; Foadi M
    Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 18. "New" platelet diseases and their biochemical aspects.
    De Gaetano G
    Acta Vitaminol Enzymol; 1973; 27(5):223-32. PubMed ID: 4596641
    [No Abstract]   [Full Text] [Related]  

  • 19. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
    Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
    Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts.
    Kaplar M; Kappelmayer J; Kiss A; Szabo K; Udvardy M
    Platelets; 2000 May; 11(3):183-4. PubMed ID: 10938896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.